Eastern European countries reimbursed these drugs later than Western European countries. Conclusion: The time from European Medicines Agency approval to reimbursement of these novel lung cancer treatments differs throughout Europe. Eastern European countries were less likely to have novel lung cancer therapies reimbursed. This research shows access to novel lung cancer therapeutics is unbalanced in Europe.
Background: Clinical guidelines for metastatic non-small cell lung cancer (NSCLC) increasingly include molecular testing for actionable biomarkers related to immuno-oncology (IO) use in lung cancer patients. While precision therapies targeting the PD-1/PD-L1 pathway have the potential to improve patient response rates, there is ambiguity regarding optimal biomarker testing and care coordination for NSCLC patients. To address this disparity in health care delivery, an online education program on molecular testing related to immunotherapies was developed for multispecialty providers. Learner responses were evaluated to determine the educational impact. Method: A thoracic surgeon, medical oncologist and pathologist developed a curriculum to address the current diagnostic landscape in IO, the value of testing and patient response rates, and how to optimize care coordination and communication among multispecialty team members. In February 2018, a live-online 1-hour video panel discussion with slides, participant polling, and live questions was produced and made available on-demand. Survey responses (pre-test, post-test, 4 weeks post-activity), polling responses, and live questions were tracked to measure knowledge gaps, lessons learned, and educational needs. Demographic information was collected for generalizability. Result: Seventy-one learners participated in the live webinar; 64 learners on-demand (n¼135). Learners were actively engaged for an average of 35.19 minutes (out of 52 minutes). Learners represented 11 unique disciplines and specialties. Most learners indicated specializing in oncology (55%), were practicing physicians (31%), and saw 1-10 new patients on an IO therapy each week (72%) in a hospital-based setting (35%). Seven audience questions were asked prior to, and during the live session. Thirty of 135 learners completed all pre/post/follow-up surveys, 96% of which reported they will actively utilize the knowledge gained into their clinical practice. Because of the education provided, learners reported improvements in their ability to: identify patients to test and treat with IO (75%), comprehend the current diagnostic landscape in IO (100%), and optimize communication and coordination of IO testing (100%). Learners also demonstrated improved comprehension via case study by identifying the optimal next step for a NSCLC clinical stage I patient referred by an oncologist for surgical resection who was found to have pleural disease intraoperatively. Conclusion: The rapid expansion of cancer immunotherapy-based options for patients with lung cancer requires providers to stay abreast on guidelines related to molecular testing. Continued refinement of care coordination practices between multispecialty team members and education on the value of molecular testing is recommended to improve the diagnosis and appropriate treatment decisions for patients with lung cancer We recently investigated contemporary practice in post-resection lung cancer surveillance, between the Society of Thoracic Surgeons (STS) and the European Society of Thoracic Surgeons (ESTS) updating a published STS survey and showed a wide variance of practice. In order to understand better the role of socio-demographics on this divergence, we aim to compare these patterns to those of members of the Japanese Association for Chest Surgery(JACS) as well as surveillance attitudes across these regions. Method: A survey identical to the one conducted in 1995 among STS members was administered via mail or electronically to members of the STS, ESTS and JACS requesting responses from those treating NSCLC. Goodness of fit tests were used to compare profiles of respondents and attitudes toward testing between groups. Multivariable logistic regression was performed to examine for predictors of guideline concordant surveillance with CT. Result: A total of 2978 STS member (response rate 7.8%, n¼234), 1450 ESTS members (response rate 8.4%, n¼122) and 272 JACS (response rate 40,8%, n¼111) members were surveyed. All three societies reported similar use of history and physical examination for asymptomatic patients (75%vs78%vs73%p¼0.52). Rate of guideline-recommended surveillance CT was reported highest among ESTS respondents for stage I patients (22% ESTS, 3% STS and 6% JACS members, p<0.01). However, both JACS and ESTS respondents reported higher rates of use of non-guidelines-recommended tests compared to STS respondents which persisted on adjusted analyses. In particular, JACS and ESTS respondents reported significantly higher use of brain MRI Regarding attitudes towards surveillance, more JACS and ESTS members either "agree" or "strongly agree" that routine testing for NSCLC recurrence results in potentially curative treatment (ESTS:86%, STS:70%, JACS:90% p<0.01). Similarly, JACS and ESTS respondents believe that surveillance would identify a curable second primary NSCLC (ESTS:94%, STS:84%, JACS:100% p<0.01) and that current literature documents definitive survival benefits from routine follow-up testing (ESTS:57%, STS:30%, JACS:62% p<0.01). Conclusion: The Japanese attitude towards surveillance is similar to that of ESTS members potentially highlighting significant differences between European and Asian surgeons compared to STS members and may be the underpinnings of routine use of nonguideline concordant surveillance. These differences clearly highlight the need of better prospective studies and joint
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Abstracts S825 recommendations to standardize practice globally. Background: Immunotherapy outcomes in non-small cell lung cancer (NSCLC) are widely available thanks to studies that got the approval of PD-1/PD-L1 inhibitors. However a careful review of ethnicity can find that most of the studies were done in Non-Hispanic White or Asian populations. There is little known about the outcomes in Hispanics (H). It is well known that Hispanics (H) in the US seem to have a lower age-adjusted mortality in NSCLC and have a different gene expression profile than NHW with higher prevalence of EGFR mutations. Method: We reviewed clinical outcomes in 216 H pts with NSCLC stage IV treated with atezolizumab, nivolumab or pembrolizumab at 4 large cancer centers (Memorial Cancer Institute, University of Miami and Moffitt Cancer Center all of them in Florida (US), and the National Cancer Institute in Peru. These patients have failed at least one line of chemotherapy previously. All of these patients did not have actionable genes (EGFR. ALK, ROS-1). We assessed overall response rate ORR (CR+PR) as main objective and disease control rate (DCR: ORR+SD), median PFS (progression free survival) and overall survival (OS) and PFS at 6m and 12m as secondary objectives. Result: Most of the pts were males: 116 (54%), 82% adenocarcinomas and the median age was 65 years (range: 37-88y). The ORR was 16% and the DCR that shows the clinical benefit was 67%. ORR and DCR were similar in adenocarcinomas (20%/ 68%) and squamous cell carcinomas (17%/64%). The progression free survival (PFS) at 6 months (m) and 12m were 80% and 56% respectively. Median PFS 14.5m and median overall survival were 19m, respectively. Conclusion: ORR for NSCLC pts treated with immunotherapy is 16% in Hispanics treated at 4 cancer centers compared to an expected 20% ORR for NHW as reported in the literature. Therefore it appears that Hispanics might not have a benefit from immunotherapy to the extent that NHWs do. We need a larger cohort and prospective studies to validate these findings. Method: This is a single-center, IRB-approved retrospective study of over 500 advanced stage (IIIBandIV) nonsquamous NSCLC patients receiving pemetrexed between May 1, 2011 to June 30, 2016 as standard of care. Patients who received at least two doses of maintenance pemetrexed were included in the analysis. Tumor response was assessed with CT scan imaging every 6-9 weeks. Hematologic indices, hepatic, renal function, performance status, dose changes, subsequent dosing or schedule changes, duration on therapy (discontinuation due to toxicity, switch in therapy or death) and overall survival data were obtained. Summary statistical analyses are provided for the demographic features of the patients included in this study in both. The difference between the two groups are evaluated using Fisher's Test /Chi-Square Test / Logistic regression analyses for categorical variable, and T-Test / Generalized Linear regression analyses for continuous variables. Generalized Linear regression model are applied to compare outcomes between outcomes SAS version 9.4 (SAS Institute, Cary, NC) will be used for statistical analyses. All tests were two-sided and performed at a nominal significance level of 0.05. Result: 138 patients were eligible to be included in the analysis. There were 90 and 48 patients who received pemetrexed q 3 weeks (group A) and q 4 weeks (group B), respectively. There were no differences in gender or ECOG performance status (PS) at baseline between the groups. Most common reasons documented for q4 week schedule are either patient preference or cumulative toxicities (lab abnormalities, poor tolerance or fatigue after induction treatment). Duration on therapy was longer in group B than in group A (282 days vs 156 days, p < 0.001). There were no differences in pre-and posttreatment changes in hemoglobin, ANC, creatinine clearance, ALT or AST levels between the two groups. There was also no difference in
